

Empagliflozin in Patients With Cirrhosis and Ascites

NCT05726032

Status	RECRUITING
Phase	Phase 2
Sponsor	Yale University
Enrollment	20 participants

Key Eligibility Criteria

Inclusion (3)

- Patients with cirrhosis and ascites on a stable dose of diuretics (spironolactone +/- loop-diuretics based on AASLD guidelines)10 and who do not require large volume paracenteses
- eGFR \geq 30mL/min/1.73 m²
- \geq 18 years old

Exclusion (21)

- Hospitalization due to a complication of cirrhosis in the previous 8 weeks (e.g. variceal hemorrhage, encephalopathy, acute kidney injury, spontaneous bacterial peritonitis)
- Direct bilirubin \geq 3 mg/dL
- Systolic blood pressure $<$ 100 mmHg
- Active malignancy including hepatocellular carcinoma undergoing treatment
- History of bladder dysfunction, incontinence, pyelonephritis, urosepsis, or frequent urinary tract infections
- ... and 16 more (see full listing online)

Locations (1 total)

Yale University, New Haven, Connecticut, United States